$1.77 EPS Expected for Celgene (CELG); Eminence Capital LP Lowered By $67.14 Million Its Anthem (ANTM) Holding

April 24, 2018 - By Linda Rogers

Celgene Corporation (NASDAQ:CELG) Logo

Analysts expect Celgene Corporation (NASDAQ:CELG) to report $1.77 EPS on May, 4 before the open.They anticipate $0.24 EPS change or 15.69% from last quarter’s $1.53 EPS. CELG’s profit would be $1.33 billion giving it 12.80 P/E if the $1.77 EPS is correct. After having $1.87 EPS previously, Celgene Corporation’s analysts see -5.35% EPS growth. The stock increased 1.26% or $1.12 during the last trading session, reaching $90.61. About 585,003 shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since April 24, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Eminence Capital Lp decreased Anthem Inc (ANTM) stake by 39.99% reported in 2017Q4 SEC filing. Eminence Capital Lp sold 298,416 shares as Anthem Inc (ANTM)’s stock declined 2.73%. The Eminence Capital Lp holds 447,815 shares with $100.76 million value, down from 746,231 last quarter. Anthem Inc now has $58.02 billion valuation. The stock decreased 0.18% or $0.42 during the last trading session, reaching $226.78. About 138,026 shares traded. Anthem, Inc. (NYSE:ANTM) has risen 35.30% since April 24, 2017 and is uptrending. It has outperformed by 23.75% the S&P500.

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 16 have Buy rating, 0 Sell and 8 Hold. Therefore 67% are positive. Anthem Inc had 75 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Cantor Fitzgerald on Friday, April 28. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, September 14 report. Jefferies maintained Anthem, Inc. (NYSE:ANTM) on Wednesday, June 7 with “Hold” rating. Oppenheimer maintained it with “Outperform” rating and $175 target in Thursday, July 30 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, October 25. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, August 17. Goldman Sachs upgraded the shares of ANTM in report on Wednesday, January 20 to “Buy” rating. Sterne Agee CRT upgraded the shares of ANTM in report on Monday, July 27 to “Buy” rating. The rating was maintained by Oppenheimer on Thursday, October 29 with “Outperform”. The company was maintained on Wednesday, January 31 by Jefferies.

Analysts await Anthem, Inc. (NYSE:ANTM) to report earnings on April, 25 before the open. They expect $4.93 EPS, up 5.34% or $0.25 from last year’s $4.68 per share. ANTM’s profit will be $1.26 billion for 11.50 P/E if the $4.93 EPS becomes a reality. After $1.29 actual EPS reported by Anthem, Inc. for the previous quarter, Wall Street now forecasts 282.17% EPS growth.

Eminence Capital Lp increased Wendys Co (NASDAQ:WEN) stake by 2.78M shares to 11.68M valued at $191.79M in 2017Q4. It also upped Liberty Media Corp Delaware stake by 2.34 million shares and now owns 8.59M shares. Yelp Inc (NYSE:YELP) was raised too.

Among 34 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 1 Sell and 14 Hold. Therefore 56% are positive. Celgene Corporation had 142 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by BTIG Research given on Thursday, August 4. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Wednesday, October 4 by RBC Capital Markets. The rating was maintained by Guggenheim with “Buy” on Thursday, December 21. The firm earned “Buy” rating on Thursday, January 25 by SunTrust. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Citigroup on Thursday, February 25. The firm earned “Hold” rating on Thursday, October 26 by Robert W. Baird. Canaccord Genuity maintained it with “Buy” rating and $140 target in Friday, October 27 report. The stock has “Outperform” rating by Leerink Swann on Friday, July 28. Cantor Fitzgerald maintained the shares of CELG in report on Tuesday, September 26 with “Buy” rating. The firm earned “Hold” rating on Friday, January 5 by Bank of America.

Since February 8, 2018, it had 1 insider purchase, and 3 sales for $3.58 million activity. $1.26 million worth of Celgene Corporation (NASDAQ:CELG) was sold by MARIO ERNEST. Shares for $299,594 were bought by Alles Mark J on Thursday, February 8. LOUGHLIN JAMES J had sold 9,250 shares worth $851,093 on Monday, March 12. Shares for $1.77M were sold by KAPLAN GILLA on Thursday, February 15.

Investors sentiment decreased to 0.83 in Q4 2017. Its down 0.34, from 1.17 in 2017Q3. It fall, as 156 investors sold Celgene Corporation shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Fifth Third National Bank & Trust has 0.58% invested in Celgene Corporation (NASDAQ:CELG). Fiera Capital holds 0.04% or 87,982 shares in its portfolio. Ledyard Bancorp holds 2,154 shares or 0.03% of its portfolio. 16,989 are held by Marshall And Sullivan Inc Wa. Cleararc Cap Inc has 17,913 shares for 0.25% of their portfolio. Smithfield accumulated 1,471 shares. Beck Mack & Oliver Limited Liability Company has 6,837 shares. Earnest Prns Llc accumulated 358 shares or 0% of the stock. 3.14 million are owned by Swedbank. Bbva Compass Bank Inc holds 0.12% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 17,788 shares. First Western Cap Mgmt holds 1.9% or 32,068 shares. Banced Corp owns 5,247 shares or 0.91% of their US portfolio. Indiana Tru Investment Management Com holds 16,003 shares or 0.77% of its portfolio. Jfs Wealth Advsr Ltd Llc invested in 20 shares. Mcf Advisors Ltd Liability Corp holds 0% or 95 shares.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $68.16 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 24.89 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>